Cargando…
Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model
The use of a 10 gene transcriptional signature as part of the GARD model has been shown to be predictive of radiotherapy benefit for a range of cancers, with the potential to determine an optimal overall dose per patient. We used publicly available RNA-seq transcriptomics data from a luminal B breas...
Autores principales: | Nolan, Ben, O’Sullivan, Brian, Golden, Aaron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396042/ https://www.ncbi.nlm.nih.gov/pubmed/36017133 http://dx.doi.org/10.1016/j.ctro.2022.08.002 |
Ejemplares similares
-
A Novel Adjustable Anthropomorphic Head Phantom for Verifying the Dose of Radiation Therapy
por: S., Abbasi, et al.
Publicado: (2020) -
Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management
por: Ahmed, Kamran A., et al.
Publicado: (2019) -
Analysis of dose distribution in organs at risk in patients with prostate cancer treated with the intensity-modulated radiation therapy and arc technique
por: Biegała, Michał, et al.
Publicado: (2016) -
Robustness of Clonogenic Assays as a Biomarker for Cancer Cell Radiosensitivity
por: Matsui, Toshiaki, et al.
Publicado: (2019) -
Estimation of the risk of secondary cancer in rectum and bladder after radiation therapy for prostate cancer using a feasibility dose–volume histogram
por: Aoyama, Takahiro, et al.
Publicado: (2023)